Nothing Special   »   [go: up one dir, main page]

HUP0101719A2 - Javított immundiagnosztikai vizsgálati eljárások redukáló ágensek alkalmazásával - Google Patents

Javított immundiagnosztikai vizsgálati eljárások redukáló ágensek alkalmazásával

Info

Publication number
HUP0101719A2
HUP0101719A2 HU0101719A HUP0101719A HUP0101719A2 HU P0101719 A2 HUP0101719 A2 HU P0101719A2 HU 0101719 A HU0101719 A HU 0101719A HU P0101719 A HUP0101719 A HU P0101719A HU P0101719 A2 HUP0101719 A2 HU P0101719A2
Authority
HU
Hungary
Prior art keywords
reducing agents
immunodiagnostic assays
improved
improved immunodiagnostic
relates
Prior art date
Application number
HU0101719A
Other languages
English (en)
Inventor
Alfons Bosman
Joost Louwagie
Geert Maertens
Erwin Sablon
Maan Zrein
Original Assignee
Innogenetics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8237028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0101719(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics N.V. filed Critical Innogenetics N.V.
Publication of HUP0101719A2 publication Critical patent/HUP0101719A2/hu
Publication of HUP0101719A3 publication Critical patent/HUP0101719A3/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgya a HCV-fertőzés kezelésének és diagnózisánakterületére esik. Közelebbről, a találmány tárgyát a HCV-NS3-helikáz ésannak alkalmazása képezi. A találmány tárgyát képezik továbbá redukálóágensek alkalmazásán alapuló javított immundiagnosztikai vizsgálatieljárások is. Ó
HU0101719A 1998-04-17 1999-04-15 Improved immunodiagnostic assays using reducing agents HUP0101719A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98870087 1998-04-17
PCT/EP1999/002547 WO1999054735A1 (en) 1998-04-17 1999-04-15 Improved immunodiagnostic assays using reducing agents

Publications (2)

Publication Number Publication Date
HUP0101719A2 true HUP0101719A2 (hu) 2001-09-28
HUP0101719A3 HUP0101719A3 (en) 2006-05-29

Family

ID=8237028

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101719A HUP0101719A3 (en) 1998-04-17 1999-04-15 Improved immunodiagnostic assays using reducing agents

Country Status (22)

Country Link
US (1) US7935490B2 (hu)
EP (2) EP1471074B1 (hu)
JP (2) JP2002512370A (hu)
KR (1) KR20010042807A (hu)
CN (1) CN1305589A (hu)
AT (2) ATE278960T1 (hu)
AU (1) AU751362B2 (hu)
BR (1) BRPI9909678B8 (hu)
CA (2) CA2324970C (hu)
CY (1) CY1108424T1 (hu)
CZ (1) CZ298268B6 (hu)
DE (2) DE69939132D1 (hu)
DK (2) DK1471074T3 (hu)
ES (2) ES2230851T5 (hu)
HK (1) HK1036653A1 (hu)
HU (1) HUP0101719A3 (hu)
IL (1) IL138791A0 (hu)
PL (1) PL343469A1 (hu)
PT (2) PT1071955E (hu)
TR (4) TR200202213T2 (hu)
WO (1) WO1999054735A1 (hu)
ZA (1) ZA200005445B (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237115T5 (es) * 1998-06-24 2008-05-16 Innogenetics N.V. Particulas de proteinas de la envoltura del hcv: uso para la vacunacion.
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
PL360990A1 (en) * 2000-08-17 2004-09-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
NZ529324A (en) 2001-04-24 2005-08-26 Innogenetics N Core-glycosylated HCV envelope proteins made in yeast cells
JP2004108914A (ja) * 2002-09-18 2004-04-08 Kudo Norio コラーゲンの測定方法
WO2004041853A2 (en) * 2002-11-08 2004-05-21 Innogenetics N.V. Hcv vaccine compositions comprising e1 and ns3 peptides
US20050014136A1 (en) * 2003-05-28 2005-01-20 Innogenetics N.V. Modified HCV NS5
CN101892199A (zh) 2003-10-28 2010-11-24 株式会社先端生命科学研究所 丙型肝炎病毒的检测方法
JP2009543099A (ja) * 2006-07-07 2009-12-03 ポール・コーポレーション 親和性捕捉中の変性剤の使用
EP2178363A4 (en) * 2007-07-16 2010-07-21 Pfizer METHOD FOR IMPROVING A GENOMMARKER INDEX OF MILK PRODUCTS AND PRODUCTS
WO2009035560A1 (en) * 2007-09-12 2009-03-19 Pfizer, Inc. Methods of using genetic markers and related epistatic interactions
BRPI0818300A2 (pt) * 2007-10-03 2017-05-09 Pfizer marcadores genéticos para gado com chifres e sem chifres e processos relacionados
WO2009085689A2 (en) * 2007-12-17 2009-07-09 Pfizer Inc. Methods of improving genetic profiles of dairy animals and products
JP5476376B2 (ja) * 2008-07-16 2014-04-23 ラジオメーター・メディカル・アー・ペー・エス 高性能固相
CN102081018A (zh) * 2009-11-30 2011-06-01 希森美康株式会社 样品的预处理方法及hcv的免疫测定方法
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
EP3213083B1 (en) 2014-10-29 2020-08-19 Abbott Laboratories Subject anti-hcv antibody detection assays employing ns3 capture peptides
CN109870581B (zh) * 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 一种定量检测HBsAg的试剂盒及方法
CN109678954B (zh) * 2018-12-29 2022-01-07 山东莱博生物科技有限公司 一对能够特异性识别hcv ns3蛋白的单克隆抗体及其应用
CN110988362B (zh) * 2019-12-20 2023-11-14 迈克生物股份有限公司 抗组蛋白抗体测定试剂、试剂盒及其使用方法
CN112225783B (zh) * 2020-09-16 2021-08-31 东莞市朋志生物科技有限公司 Hcv重组抗原及其突变体
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN113219169B (zh) * 2021-05-22 2021-12-17 北京金诺百泰生物技术有限公司 生物检测用封闭剂及其制备方法、包被板及应用该包被板的试剂盒
CN115112897B (zh) * 2021-12-10 2024-11-01 中山大学附属第八医院（深圳福田） 一种用于鉴别抗体检测生物学假阳性的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139526A2 (en) * 1983-10-20 1985-05-02 Warner-Lambert Company An insolubilized stable specific binding protein
US4616078A (en) * 1985-04-08 1986-10-07 Eli Lilly And Company Process for purifying proinsulin-like materials
CA1340877C (en) * 1987-12-28 2000-01-18 Takashi Sugiyama Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
ATE92633T1 (de) * 1988-05-11 1993-08-15 Abbott Lab Verfahren zur erhoehung der spezifizitaet in kompetitiven immuntests.
US4923967A (en) * 1988-09-26 1990-05-08 Eli Lilly And Company Purification and refolding of recombinant proteins
US6194140B1 (en) * 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
ATE270326T1 (de) 1990-04-04 2004-07-15 Chiron Corp Protease von hepatitis-c-virus
US5606031A (en) * 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
HU227547B1 (en) * 1991-06-24 2011-08-29 Novartis Vaccines & Diagnostic Hepatitis c virus (hcv) polypeptides
JP3225468B2 (ja) 1992-08-28 2001-11-05 ダイナボット株式会社 抗体測定用試薬
ATE552340T1 (de) 1993-04-27 2012-04-15 Innogenetics Nv Hepatitis c virus genotypsequenzen sowie ihre verwendung als behandlungs- und nachweismitteln
ATE274578T1 (de) 1993-11-04 2004-09-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
DE69429017T2 (de) 1994-06-23 2002-07-04 Energy Answers Corp., Albany Anlage zur erzeugung von asche enthaltenden produkten und energie aus abfällen
PT721505E (pt) * 1994-07-29 2002-10-31 Innogenetics Nv Proteinas do envelope do virus da hepatite c purificadas para utilizacao em diagnostico e terapeutica
DE4428705A1 (de) * 1994-08-12 1996-02-15 Boehringer Mannheim Gmbh Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
JPH0862219A (ja) 1994-08-19 1996-03-08 Dainabotsuto Kk 還元型抗原に対する抗体アッセイ試薬及びそれを使用した測定方法
US7129337B1 (en) 1994-10-21 2006-10-31 Innogenetics N.V. Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5705330A (en) * 1995-04-14 1998-01-06 Abbott Laboratories Chemiluminescent immunoassay for antibody detection
US5616460A (en) 1995-06-07 1997-04-01 Abbott Laboratories Buffer composition for reagents for immunoassay
ATE311463T1 (de) 1996-05-24 2005-12-15 Chiron Corp Fusionsprotein mit multiplen epitopen
WO1998030356A1 (en) * 1997-01-13 1998-07-16 Rodel, Inc. Polymeric polishing pad having photolithographically induced surface pattern(s) and methods relating thereto

Also Published As

Publication number Publication date
AU3817199A (en) 1999-11-08
TR200202213T2 (tr) 2002-11-21
ES2230851T3 (es) 2005-05-01
ZA200005445B (en) 2003-01-06
ATE401340T1 (de) 2008-08-15
ES2310701T3 (es) 2009-01-16
ATE278960T1 (de) 2004-10-15
BR9909678A (pt) 2000-12-19
US20060263854A1 (en) 2006-11-23
KR20010042807A (ko) 2001-05-25
EP1471074A2 (en) 2004-10-27
DE69939132D1 (de) 2008-08-28
BRPI9909678B8 (pt) 2021-05-25
WO1999054735A1 (en) 1999-10-28
EP1071955B1 (en) 2004-10-06
TR200101647T2 (tr) 2002-06-21
US7935490B2 (en) 2011-05-03
AU751362B2 (en) 2002-08-15
TR200101648T2 (tr) 2002-06-21
CZ298268B6 (cs) 2007-08-08
PT1071955E (pt) 2005-02-28
CA2324970C (en) 2009-06-30
EP1071955B2 (en) 2009-02-18
DK1071955T3 (da) 2005-02-07
HUP0101719A3 (en) 2006-05-29
CA2324970A1 (en) 1999-10-28
EP1471074B1 (en) 2008-07-16
DE69920895T2 (de) 2005-10-13
IL138791A0 (en) 2001-10-31
CY1108424T1 (el) 2014-04-09
DE69920895T3 (de) 2009-09-03
EP1071955A1 (en) 2001-01-31
CN1305589A (zh) 2001-07-25
JP3974620B2 (ja) 2007-09-12
PT1471074E (pt) 2008-10-23
CA2658218C (en) 2014-10-28
EP1471074A3 (en) 2004-11-10
BR9909678B1 (pt) 2013-11-12
HK1036653A1 (en) 2002-01-11
PL343469A1 (en) 2001-08-13
ES2230851T5 (es) 2009-06-25
DE69920895D1 (de) 2004-11-11
CZ20003819A3 (cs) 2001-10-17
TR200003024T2 (tr) 2000-12-21
DK1471074T3 (da) 2008-11-17
CA2658218A1 (en) 1999-10-28
DK1071955T4 (da) 2009-06-15
JP2002512370A (ja) 2002-04-23
JP2005185285A (ja) 2005-07-14

Similar Documents

Publication Publication Date Title
HUP0101719A2 (hu) Javított immundiagnosztikai vizsgálati eljárások redukáló ágensek alkalmazásával
HUP0400719A2 (hu) Vegyületek és eljárások Chlamydia-fertőzés diagnosztikájára és kezelésére
DK0804584T3 (da) Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler
ATE299594T1 (de) Verbesserungen von screeningsverfahren für papillomviren
ATE418565T1 (de) Antikörper gegen nichtfunktionelle p 2 x 7 rezeptoren, diagnose und behandlung von krebs und anderen leiden
HUP0101521A2 (hu) A Mycobacterium tuberculosis antigének fúziós fehérjéi és felhasználásuk
DK1088077T3 (da) Infektiöse Newcastle disease-viruskloner, vacciner og diagnostiske analyser
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
HUP0500444A2 (hu) HCV antigén/ellenanyag-kombinációs esszé
EP1141699A4 (en) DEVICES AND METHODS FOR PERFORMING METHODS FOR DETERMINING BLOOD COAGULATION BY PIEZOELECTRIC DETECTION
HK1035662A1 (en) Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial uc panca antigens
EP1555325A4 (en) NOVEL PEPTIDE FRUCTOSYL-OXIDASE AND USE THEREOF
DE3861132D1 (de) Dismulgierendes und reinigungsmittel, verwendbar zur trennung von erdoel-wasser-gemischen, gegebenenfalls emulsionen und anwendungen dieses mittels.
SE9103332D0 (sv) Method for the diagnosis of blood coagulation desorders
GB9524934D0 (en) Treatment and diagnosis of infections due to helicobacter pylori
DK1037916T3 (da) Erythrovirus og dets anvendelser
PT946874E (pt) Diagnostico de helicobacter pylori
EA200600639A1 (ru) Пептид, происходящий из вируса гепатита с
NO20005608D0 (no) Strukturelle proteiner fra fisk-pankreatisk-sykdomsvirus og anvendelser derav
DE50007635D1 (de) Verfahren zur diagnose von sjögren-syndrom
BR0314166B8 (pt) teste de hcv
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
ATE256704T1 (de) Antikörper und diagnostizierverfahren zur pestivirusdiagnose
AU2002365941A8 (en) Methods of diagnosis, monitoring and treatment of fertility
ATE315093T1 (de) Hcv ns2/3 fragmente und ihre verwendungen

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees